Marie Fournier
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Impact of Diffusing Lung Capacity for Carbon Monoxide on Mortality Risk in Patients with ASMD: Insights from a Post Hoc Analysis.
Journal: Advances in therapy
Published: September 24, 2025
Survival of patients with chronic acid sphingomyelinase deficiency (ASMD) in the United States: A retrospective chart review study.
Journal: Molecular genetics and metabolism reports
Published: December 14, 2023
A retrospective study of morbidity and mortality of chronic acid sphingomyelinase deficiency in Germany.
Journal: Orphanet journal of rare diseases
Published: December 01, 2023
Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD).
Journal: The European journal of health economics : HEPAC : health economics in prevention and care
Published: June 07, 2023
Re: The budget impact of enzyme replacement therapy in type 1 gaucher disease in the United States.
Journal: Journal of medical economics
Published: April 03, 2023
Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims Analysis.
Journal: Advances in therapy
Published: November 16, 2022
Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective.
Journal: Journal of medical economics
Published: October 13, 2021
Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Journal: Journal of managed care & specialty pharmacy
Published: October 31, 2019
Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient.
Journal: ClinicoEconomics and outcomes research : CEOR
Published: February 22, 2019
Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
Journal: Advances in therapy
Published: February 08, 2019
Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.
Journal: Journal of medical economics
Published: April 09, 2015
Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.
Journal: German medical science : GMS e-journal
Published: August 22, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026